Microba Life Sciences Limited (AU:MAP)
ASX:MAP
Want to see AU:MAP full AI Analyst Report?
MAP Stock Chart & Stats
AU$0.08
>-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.16
Previous CloseN/A
Volume476.46K
Average Volume (3M)469.77K
Market Cap
AU$42.63M
Enterprise ValueAU$28.02M
Total Cash (Recent Filing)AU$11.27M
Total Debt (Recent Filing)AU$3.31M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding608,963,000
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.14Price Target Upside68.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$16.80M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsMicroba’s business model spans clinical/consumer testing, B2B research services and biopharma collaborations. That structural diversification supports multiple, complementary revenue channels and reduces reliance on a single market, aiding resilience and scalable growth over the next 2–6 months.
Low Financial LeverageA 0.10 debt-to-equity ratio provides durable financial flexibility for a life sciences firm that may need to fund R&D or extend commercialization timelines. Low leverage reduces refinancing risk and preserves capacity to raise targeted capital or absorb temporary revenue shortfalls without aggressive deleveraging.
Positive Free Cash Flow GrowthReported free cash flow growth and FCF exceeding net income indicate the company can generate cash beyond accounting losses. Over months this suggests operational improvements or working-capital gains that can fund near-term operations, strengthening sustainability while margins and revenues recover.
Bears Say
Declining RevenueA substantial revenue decline undermines scale economics and the company’s ability to spread fixed R&D and lab costs. Persisting top-line contraction over several quarters can weaken competitive positioning, constrain investment in product development or commercial expansion, and stress medium-term viability.
Negative Operating Cash FlowSustained negative operating cash flow signals the core business is not yet cash-generative and can consume liquidity. Over a 2–6 month horizon this raises the likelihood of external financing, potential dilution, or reduced R&D/commercial spend unless OCF reverses, making execution and runway a structural risk.
Persistent UnprofitabilityContinued negative margins and ROE indicate the company has yet to achieve operational leverage or profitability. This erodes shareholder returns and may limit ability to secure favourable partnership economics or non-dilutive funding, posing a medium-term constraint on scaling commercial and R&D programs.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.07 and its highest was AU$0.15 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$42.63M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
Microba Life Sciences Limited’s upcoming earnings report date is Sep 01, 2026 which is in 98 days.
How were Microba Life Sciences Limited’s earnings last quarter?
Microba Life Sciences Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.018 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.008.
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 608,963,000 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Microba Life Sciences Limited reported an EPS of -AU$0.018 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 1.176%.
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.14 (68.75% Upside)
AU$0.14 (68.75% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.76%
12-Months-Change
Fundamentals
Return on Equity
-63.04%
Trailing 12-Months
Asset Growth
-14.63%
Trailing 12-Months
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.14
▲(68.75% Upside)
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Options Prices
Currently, No data available
---